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Abstract
Background: Giant cell tumor of the bone (GCTB) is classified as an intermediate, locally aggressive but rarely
metastasizing tumor. The mainstay of treatment for the treatment of GCTB had been the surgical removal until
an anti- receptor activator of nuclear factor-kappa B ligands (RANKL) antibody denosumab was developed. And
favorable responses and the possibility of surgical downstaging have been reported. However, the long-term
outcome of denosumab has not yet been confirmed and moreover the long-term clinical outcome after the
recurrence of GCTB in the era before molecular target therapy is still uncertain. The aim of this study was to
evaluate the long-term clinical outcome of recurrent GCTB of the extremity in the era before molecular target
therapy and to determine the factors that affect the repetitive recurrence and sacrifice of adjacent joints.
Methods: This multicenter study focused only recurrent GCTB of the extremity with no medical treatment and
included 103 patients treated from 1980 to 2008.
Results: Thirty-two (31.1 %) patients developed repetitive recurrences after salvage surgery. Second curettage
and venue of initial surgery (non-cancer hospital) were both significantly correlated with repetitive recurrence in
univariate (P = 0.034 and P = 0.002) and multivariate (P = 0.004 and P = 0.001) analyses. Seventy-two (76.6 %) of 94
patients achieved successful preservation of adjacent joints. Campanacci Grade III was significantly correlated with
sacrifice of the adjacent joint by univariate statistical analysis (P = 0.019), although its impact was only marginally
significant by multivariate analysis (P = 0.059). Seventeen patients (16.5 %) developed distant metastasis, and one
patient (0.97 %) developed malignant transformation. Finally, 94/103 patients (91.3 %) with recurrent GCTB were
successfully rendered NED by further surgical treatment.
Conclusions: We concluded that repetitive, thorough curettage with surgical adjuvant treatment resulted in a
favorable rate of adjacent joint preservation (76.6 %), but recurettage inferred a risk of repetitive recurrences.
Although the treatment strategy against the recurrent GCTB is being updated with denosumab, we believe that
our data will be useful for future comparisons with the long-term clinical benefit of denosumab.
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Background
Giant cell tumor of the bone (GCTB) is classified as an
intermediate, locally aggressive but rarely metastasizing
tumor. It accounts for 4–5 % of primary bone tumor and
20 % of all benign tumors [1]. The mainstay of treatment
for the treatment of GCTB had been the surgical removal.
To reduce local recurrence, a variety of adjuvant treat-
ments using phenol, liquid nitrogen, high-speed burr, or
methylmethacrylate cement have been established [2–4].
The advantage of these adjuvant treatments in the treat-
ment of GCTB has generally been accepted in the field. It
has been reported that adjuvant treatment contributes to
better prevention of local recurrence (0–34 %) [4, 5] than
treatment without adjuvants (12–47 %) [5–8] GCTB
expresses receptor activator of nuclear factor-kappa B
(RANK) and stromal cells that express RANK ligands
(RANKL) [9]. Therefore, an anti-RANKL antibody deno-
sumab was developed for the treatment of GCTB [10].
The favorable responses and the possibility of surgical
downstaging were reported [11, 12]. Although denosumab
was predicted to reduce osteolysis and control disease
progression in patients with GCTB, the long-term out-
come of denosumab has not yet been confirmed. On the
other hand, there is little data of the long-term clinical
outcome of GCTB after recurrence including the rate of
sacrificing adjacent joint due to the additional surgical
treatment. The purpose of this study was to evaluate the
long-term clinical outcome of recurrent GCTBs of the
extremity in the era before molecular target therapy and
to determine the factors that influence repetitive recur-
rence and sacrifice of adjacent joint.
Methods
Data regarding age, gender, location, Campanacci grade
[5], initial treatment, venue of initial treatment, time to
local recurrence, treatment of recurrence, number of
recurrences, distant metastasis, malignant transform-
ation, term of follow-up, and outcome were collected by
questionnaire from the 20 cancer centers and university
hospitals that participate in the Japanese Musculoskeletal
Oncology Group (JMOG) network. Campanacci grade is
based on the radiographic appearance. Grade I tumor is
associated with a well-marginated border of a thin rim of
mature bone and the cortex is intact or slightly thinned
but not deformed. Grade II tumor appears relatively well-
defined margins but no radiopaque rim. Grade III tumors
has fuzzy borders [5]. The inclusion criterion was histo-
logically proven recurrent GCTB in the extremities with
no medical treatment. A total of 138 patients were treated
for recurrent GCTB from 1980 to 2008. We excluded
cases with tumors at axial sites (N = 4) and cases of recur-
rence in soft tissue (N = 6). We excluded another 25
patients because of lack of information with regards to
Campanacci grade. Therefore, we reviewed 103 patients in
this study.
We divided the patients into two groups depending on
the anatomical site of the disease to evaluate the risk of
sacrificing the major joints: site A included the distal
radius, proximal humerus, proximal femur, distal femur,
proximal tibia, and distal tibia and site B included the
ulna, fibula, and talus (Table 1). Site A is adjacent to large
joints, including the wrist, shoulder, hip, knee, and ankle
which cause severe loss of limb function after being sacri-
ficed, whereas site B includes all other small joints [13].
Disease-free survival after the second surgery was de-
fined as the time interval from the second surgery to the
second recurrence as analyzed using the Kaplan–Meier
method, and the factors influencing repetitive recurrence
(more than two recurrences) were determined by uni- and
multivariate analyses. The chi-square test and logistic
analysis were used to determine the factors influencing
the preservation of adjacent joint (site A).
Statistical significance was defined by probability (P)
values ≤ 0.05. Data were analyzed with Statistical Package
for Social Sciences (SPSS) for Windows (version 19;
SPSS Inc., Chicago, IL, USA).
Results
The study included 53 males and 50 females, with a me-
dian age of 34 years (range, 12–82 years), and the median
follow-up period was 114 months (range, 11–408 months).
Anatomical locations included the upper extremity in 23
patients and the lower extremity in 80 patients (Table 1).
Ninety-one patients underwent primary treatment at our
group’s institution (Group P). Twelve patients were re-
ferred to our group’s institution with recurrence of GCTB
after treatment elsewhere (Group R).
Table 1 Distribution of anatomical sites (N = 103)
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Ninety-five patients were included in site A and 8
patients in site B (Table 1). The second surgery included
curettage in 85, en-bloc excision in 17, and amputation
in one patient (Fig. 1). Thirty-two patients developed a
second recurrence (29 patients in site A and three
patients in site B). The third surgery included curettage
in twenty-seven patients, and en-bloc excision in five
patients. Eleven patients developed a third recurrence
(eight patients in site A and three patients in site B). The
forth surgery included curettage in nine patients, and en-
bloc excision in two patients. One patient developed
malignant transformation after the third surgery, and
therefore, amputation was performed. One patient deve-
loped a forth recurrence and was treated by recurettage.
Factors influencing re-recurrence-free survival as iden-
tified by univariate analysis included the venue of primary
treatment and procedure of second surgery (Table 2).
Multivariate analysis revealed that age (≥35 y.o., P = 0.006),
Group R (P < 0.001) and second curettage (P = 0.004) were
independent predictors of worse re-recurrence-free survival
(Table 2).
Next, we examined the factors influencing sacrifice of
the adjacent joint in the 94 patients in site A. One patient
in site A had his adjacent joint sacrificed at the time of
initial surgery; therefore, we excluded this patient from
the analysis. Fifty-three of 94 patients achieved preserva-
tion of the adjacent joint after the second surgery. To this
end, 13/25 and 5/8 patients achieved preservation of the
adjacent joint after the third and fourth surgery, respec-
tively (Fig. 1). Hence, successful preservation of the adja-
cent joint was achieved in 72/94 patients (76.6 %). Factors
influencing sacrifice of the adjacent joint as identified by
chi-square analysis included Group R (P = 0.036) and
Campanacci grade III (P = 0.019) (Table 3). Multivariate
analysis revealed Campanacci grade III (P = 0.059) as a
marginally significant predictor of adjacent joint sacrifice
(Table 3). In this study, the highest rate of joint sacrifice
was observed for the proximal femur (55.6 %), whereas
the rate of the other joints ranged from 0 to 28.6 %
(Table 4).
The number of patients who developed distant metas-
tasis in the absence of malignancy was 17 (16.5 %; lung
Fig. 1 Flowchart of treatment course. (Rec, recurrence; En-bloc, En-bloc excision)
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Table 2 Factor analysis for repetitive recurrence
Univariate analysis Cox proportional hazards regression analysis








95 % CI P value
Age
< 35 y.o. 66 (18) 0.626 0.332
≥ 35 y.o. 37 (14) 0.594 7.526 1.119 3.062 1.377–6.811 0.006
Gender
Male 53 (13) 0.656 0.341
Female 50 (19) 0.581
Tumor site
Upper extremity 79 (23) 0.591 0.089
Lower extremity 24 (9) 0.636
Tumor location
Site A 95 (29) 0.616 0.557
Site B 8 (3) 0.625
Campanacci
I 12 (4) 0.550 0.433
II 71 (19) 0.657
III 20 (9) 0.524
Initial procedure
Curettage 98 (30) 0.603 0.785
En bloc excision 5 (2) 0.800
Status
Group P 91 (24) 0.682 0.002
Group R 12 (8) 0.563 10.831 1.625 5.078 1.929–13.363 < 0.001
Second surgery
Curettage 84 (29) 0.541 0.034 8.522 2.054 8.522 1.964–30.590 0.004
En-bloc excision 19 (3) 0.872
Table 3 Analysis for joint preservation
N = 95 Joint status after
final surgery
Chi-square analysis Logistic analysis
Preserve Sacrifice P value X2 value Standardized coefficient (B) Relative risk (eB) 95 % CI P value
Age grade ≤ 35 50 12
> 35 22 10 0.197 1.666 0.934 2.546 0.853–7.600 0.094
Gender F 37 8
M 35 14 0.217 1.524 0.575 1.777 0.606–5.209 0.295
Patient status Group P 67 17
Group R 5 5 0.036 4.415 0.987 2.683 0.548–13.139 0.223
Campanacci Grade I or II 62 14
III 10 8 0.019 5.498 1.172 3.230 0.957–10.903 0.059
Recurrence type Repetitive 19 9 0.0192 1.699 0.475 0.622 0.200–1.930 0.411
Single 53 13
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metastasis in 15, bone metastasis in one, and both types
of metastasis in one patient). Nine patients received
pulmonary metastasectomy, and the disease was conser-
vatively controlled in eight patients; all are still alive after
a mean follow-up period of 78 months, with 10 patients
having no evidence of the disease (NED), six patients are
alive with the disease (AWD), and one patient has died
because of the disease (DOD). The final status of the
patients is as follows: NED, 94 patients; AWD, 8
patients; DOD, 1 patient.
Discussion
In this study, we found that repetitive recurrence was
not a risk factor for sacrifice of the adjacent joint (wrist,
shoulder, hip, knee, and ankle) and the adjacent joint
was still preserved in 76.6 % of the patients who had
received an initial surgery with curettage. Initial treat-
ment venue (Group R) and Campanacci Grade III were
both risk factors for sacrificing the adjacent joint by
univariate analysis, although the impact of Campanacci
Grade III was only marginally significant by multivariate
analysis.
Prior to the introduction of denosumab, the clinical
outcome of treatment for recurrent GCTB has been
reported in several papers. Prosser et al. [8] performed
repeat curettage after local recurrence of GCTB in 43
cases, with a success rate of 100 % in patients who previ-
ously had curettage and 79.3 % in patients referred from
elsewhere. McGough et al. [14] treated 45 cases of recur-
rent GCTB and found that incomplete initial surgery, a
delay of more than 6 months in the diagnosis of recur-
rence, and subchondral recurrence of the tumor were
factors contributing to the failure to salvage the joint.
We previously reported the clinical outcome of recur-
rent GCTB in the extremities treated by the Eastern
Asian Musculoskeletal Oncology Group (EAMOG). We
retrospectively reviewed 110 patients and analyzed the
factors influencing the number of recurrences and distant
metastasis. In that study, 98/110 patients (89.1 %) were
successfully rendered NED by further treatment. The adja-
cent joint (wrist, shoulder, hip, knee, and ankle) was still
preserved in 48.5 % of the patients who had received
initial surgery with curettage. The initial treatment venue
(Group R) was a risk factor for sacrificing the adjacent
joint [15].
The site of the tumor, particularly the proximal femur,
may be a factor influencing the risk of sacrificing the
adjacent joint. Errani et al. [16] reported a high recur-
rence rate in the proximal femur compared with that in
other sites. They also mentioned that special attention
must be given to the proximal femur because of the diffi-
culties in treating it. In the present study, 22/94 patients
eventually required amputation, prosthetic replacement,
or arthrodesis. Although the indications of these pro-
cedures were not standardized across all centers, the
venue of the initial treatment (Group R) (P = 0.036) and
Campanacci grade III (P = 0.019) were both risk factors for
adjacent joint sacrifice in univariate analysis. The repeated
curettage was related to repetitive recurrence; however,
repetitive recurrence was not associated with sacrifice of
adjacent joints. The primary surgery with careful follow-up
is critical in preventing resection of the adjacent joint and
maintaining the function of the joint. Treatment for recur-
rent GCTB of the extremities should aim to preserve the
function of the adjacent joint by meticulous curettage with
adjuvant treatment.
It this study, the incidence of lung metastasis appears to
be high (14.6 %) compared with the previously reported
incidence in the general GCTB population (approximately
3 %) [8, 17]. Although the cohort of patients in this study
included only those with recurrent GCTB which may
represent a selection bias towards patients with a higher
risk of developing metastasis, there are several papers
reported the relationship between local recurrence and
metastasis [16–19].
Most cases of malignant transformation of GCTB
occur after radiation treatment, and high-grade malig-
nant transformation in the absence of previous irra-
diation is very rare [20]. Bertoni et al. [21] reported six
cases of postsurgical secondary malignant GCTB with-
out prior irradiation. They also mentioned that the
average interval between the diagnosis of benign GCTB
and that of sarcoma of these patients was 18 years,
which is much longer than the average interval observed
in patients who receive previous radiotherapy (9 years).
In this study, one patient (0.97 %) developed malignant
transformation without prior irradiation.
Table 4 Joint status after final surgery by location and
Campanacci grade







Humerus/Proximal (N = 6, 16.7 %) II 5 1
Radius/Distal (N = 12, 16.7 %) II 9 0
III 1 2
Femur/ Proximal (N = 9, 55.6 %) II 3 5
III 1 0
Femur/Distal (N = 28, 28.6 %) I 6 0
II 9 5
III 5 3
Tibia/Proximal (N = 37, 18.9 %) I 1 1
II 26 3
III 3 3
Tibia/Distal (N = 3, 0 %) I 1 0
II 2 0
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With GCTBs expressing RANK and stromal cells ex-
pressing RANKL [9], the anti-RANKL antibody (deno-
sumab) was introduced for the treatment of GCTB
[10], and favorable responses were reported [11, 12].
Rutkowskiet et al. [12] reported that among patients with
resectable GCTB treated with denosumab and for whom
curative intent surgery was planned and believed to be
associated with significant morbidity before enrollment,
48 % had not yet undergone surgery altogether and
remained on monthly denosumab treatments at the time
of the data cutoff. Moreover, another 38 % patients were
treated with denosumab and underwent a less invasive
surgical procedure than was planned at the time of ente-
ring the study. Denosumab is predicted not only to the
reduce osteolysis and control disease progression in
patients with GCTB but also to ameliorate the clinical
outcome of recurrent GCTB. However, further studies are
still warranted to determine the long-term outcome of
denosumab. This study will be useful for future studies
evaluating the long-term clinical benefit of denosumab.
A limitation of this study is that it was a multicenter
retrospective study with no randomization protocol of
surgical procedures. Thus, the indication of the surgery
(recurettage or en bloc excision) was not identical across
the centers. The final decision of the type of surgery was
made by the operating surgeon in each institution.
Although the total number of patients was relatively
large for recurrent GCTB, the sample size in each joint
was relatively small to draw conclusions. In cox propor-
tional hazards regression analysis, 32 events (repetitive
recurrence) provided a 80 % power to detect a relative
risk of 2.7 in re-recurrence-free survival.
Conclusions
In this cooperative study, recurettage inferred a risk of
repetitive recurrences but not of having the adjacent joint
sacrificed. Repetitive, thorough curettage with surgical
adjuvant treatment resulted in a favorable rate of adjacent
joint preservation. Although the treatment strategy against
the recurrent GCTB will be changed with denosumab, we
believe that our data will be useful for future comparisons
with the long-term clinical benefit of denosumab.
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